⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685706 | 0.89 | — | — | |
| SCHEMBL1577820 | 0.78 | — | — | |
| SCHEMBL2306907 | 0.72 | — | — | |
| SCHEMBL378435 | 0.72 | — | — | |
| SCHEMBL4189631 | 0.72 | — | — | |
| SCHEMBL7504428 | 0.71 | — | — | |
| SCHEMBL4162255 | 0.69 | MGLL (0.30) | — | |
| SCHEMBL678889 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL27435759 | 0.69 | — | — | |
| SCHEMBL4178502 | 0.69 | MGLL (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | claimed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| CN-113264921-A | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-106573914-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3418279-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | Respivert Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| US-7144887-B2 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2006-12-05 | — | — | US | disclosed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20030125333-A1 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2003-07-03 | — | — | US | disclosed |
| EP-1242423-A1 | SUBSTITUTED 1,2,3-TRIAZOLO 1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044250-A1 | SUBSTITUTED 1,2,3-TRIAZOLO[1,5-a]QUINAZOLINES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |